Log In
Print
BCIQ
Print
Print this Print this
 

ONT-10

  Manage Alerts
Collapse Summary General Information
Company Oncothyreon Inc.
DescriptionLiposomal glycolipopeptide cancer vaccine targeting mucin 1 (MUC1; CD227)
Molecular Target Mucin 1 (MUC1) (CD227)
Mechanism of ActionVaccine
Therapeutic ModalityActive immunotherapy
Latest Stage of DevelopmentPhase I
Standard IndicationSolid tumors
Indication DetailsTreat solid tumors
Regulatory Designation

Partner


 Product Details
 Archive Items are loading loading
Get a free BioCentury trial today